Welcome to the IMPACT Pilot Study!

The Icosapent Ethyl for the Management and Prevention of Atherosclerotic Cardiovascular Disease Trial (IMPACT) Pilot is being conducted in preparation for a possible large-scale clinical trial. The IMPACT Pilot will compare the success rate of three different recruitment methods and deploy a brief screening questionnaire. Participants who are willing to provide medical records to confirm medical conditions that are entry criteria for the future trial will be asked to consent to medical record review. This is an important but optional component of IMPACT Pilot.

Participants at HopeHealth (Florence, SC) are also being evaluated in person (HopeHealth, SC). Please see HopeHealth tab.

If funded by the National Institutes of Health (NIH), IMPACT will test whether high-dose icosapent ethyl, a highly purified form of the omega-3 fatty acid eicosapentaenoic acid (EPA), reduces rates of cardiovascular events in 14,000 high-risk patients.